Mesoblast Limited
(ASX:MSB) has welcomed news the Japanese Patent Office has allowed a key patent for the use of its proprietary adult mesenchymal precursor cells.
The regenerative medicine company says the patent is for the treatment of heart diseases, stroke and other vascular conditions.
The patent provides commercial rights in Japan until at least March 2024 and has the potential for the patent term to be extended.
Mesoblast says the patent extends and broadens its intellectual property position in Japan and will further strengthen its commercial strategy in the country.
Mesoblast reported a net loss of $50.81 million in the first half of the 2015 financial year.
